West Nile Virus (WNV) is a mosquito-borne zoonotic arbovirus potentially endemic to around 83 countries worldwide including the USA, Canada and parts of Europe. WNV infections in humans are mainly asymptomatic. Clinical disease ranges from a mild febrile illness to severe encephalitis (neuroinvasive disease) which occurs in approximately 1 in 150 people infected. In the US between 1999-2009 WNV has caused 29,606 clinical cases and 1,423 deaths (CDC Figures). Due to high attention in the media, especially during the summer of 2012 there are many calls for the further development of a WNV preventative vaccine.
This MarketVIEW is a comprehensive MS Excel-based model + summary presentation which forecasts the potential
commercial value of West Nile Virus (WNV) vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates for LO/BASE/HI uptake scenarios per target age group(s). The product also includes an up-to-date review of latest competitor activity in the field and West Nile Virus (WNV) epidemiolog in the US/Canada and other major WNV endemic countries.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL